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Abstract 
Background: Systemic lupus erythematosus (SLE) is a remarkably heterogeneous autoimmune disease. Despite tre-
mendous efforts, our knowledge of serum protein patterns in severe SLE phenotypes is still limited. We investigated 
the serum protein pattern of SLE, with special emphasis on irreversible organ damage and active lupus nephritis (LN) 
as assessed by renal Systemic Lupus Erythematosus Disease Activity Index.
Methods: We used proximity extension immunoassay (PEA, Proseek Multiplex, Olink) to assess the serum levels 
of ninety-two inflammation-related proteins in Czech patients with SLE (n = 75) and age-matched healthy control 
subjects (n = 23). Subgroup analysis was carried out on the basis of organ damage (with/without, 42/33) and biopsy-
proven LN (with/without, 27/48; active LN, n = 13; inactive LN, n = 14).
Results: Of thirty deregulated proteins between SLE and the healthy controls (Pcorr < 0.05), the top upregulated 
proteins in SLE were sirtuin 2, interleukin 18 (IL18), and caspase 8 (Pcorr < 0.0006). Of these, sirtuin 2 and caspase 8 had 
not yet been reported with SLE. Elevated levels of IL8, CCL2/MCP1, CCL11, and MMP10 (Pcorr < 0.05) were detected in 
patients with organ damage for which the serum levels of CCL11 and MMP10 were particularly informative in organ 
damage prediction. Comparing patients based on LN, elevated levels of CSF1, sIL15RA, sCD40, sCX3CL1, caspase 8, 
sIL18R1, bNGF, and GDNF (Pcorr < 0.05) were detected in active LN. Except GDNF, all LN-associated markers showed 
usefulness in prediction of active renal disease.
Conclusions: This highly sensitive PEA analysis identified the serum pattern of SLE, organ damage, and active LN, 
with many novel candidate proteins detected. Their exact role and suitability as biomarkers in SLE deserve further 
investigation.
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Background
Systemic lupus erythematosus (SLE) is a serious, com-
plex, multi-system autoimmune rheumatic disease with 
significant variability in the phenotypes and severity of 
the disease. The greatest challenges continue to be the 
prevention and management of irreversible organ dam-
age and active lupus nephritis (LN), one of the most 
feared phenotypes in SLE.
Organ damage is a primary outcome in SLE, which is 
accrued not only during the disease course, but also by 
therapy itself [1]. Early damage is more likely to be linked 
to active inflammation, while late irreversible dam-
age is often attributable to the side effects of drugs and 
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especially to chronic and cumulative corticosteroid expo-
sure [2]. The Systemic Lupus International Collaborating 
Clinics/American College of Rheumatology SLICC/ACR 
Damage Index (SDI), divided into 38 items grouped in 
12 organ systems, is a valid measure of irreversible organ 
damage in SLE [1]. Despite improvement in the survival 
of SLE patients in recent decades, significantly higher 
morbidity and mortality are reported in patients develop-
ing irreversible organ damage [1]. The patterns of organ 
damage vary among populations [3–5], but the musculo-
skeletal, cardiovascular, and renal systems are those most 
frequently affected [6]. Nowadays, prevention of irrevers-
ible damage is a major goal in the management of SLE 
patients and identification of the key molecules involved 
in the pathogenesis of organ damage is needed.
Lupus nephritis is a major manifestation associated 
with higher morbidity and mortality of SLE patients [7]. 
It has a considerable influence on treatment decisions, as 
well as long-term outcomes. The effective treatment of 
LN requires a correct diagnosis, timely intervention, and 
early treatment of any disease relapse. Renal biopsy is still 
the gold standard for diagnosis and deciding on therapy 
in LN but its invasive nature prevents it from being used 
repetitively in many cases [8]. Traditional clinical param-
eters such as proteinuria, glomerular filtration rate, urine 
sediments, anti-dsDNA antibodies, and complement lev-
els are not sensitive or specific enough to detect activity 
and early relapse of LN [9, 10]. Novel serum and urinary 
biomarkers such as cytokines and chemokines CCL2 [11], 
CCL3, CCL5 [12], IL17 [11], BLyS, APRIL [13], growth 
factor TGFβ [11] and others (TWEAK [14], IGFBP2 [15], 
OPG [16]) have recently been nominated for diagnosis 
and monitoring of LN. Although intensively investigated 
[17, 18], only a few biomarkers have been assessed for 
prediction of renal activity or prognosis. Identification 
of novel and reliable biomarkers or their combinations 
for LN reflecting also disease activity is, therefore, highly 
desirable.
In this study we aimed to assess the serum protein 
pattern of SLE using a highly sensitive multiplex prox-
imity extension immunoassay (PEA) on 92 inflammation-
related proteins. Special emphasis was given to serum 
patterns associated with irreversible organ damage and 
LN reflecting the renal disease activity and their useful-
ness in the prediction of these severe phenotypes.
Methods
Study population and materials
Serum samples were obtained from 75 Czech SLE 
patients; all enrolled patients fulfilled the ACR classifica-
tion criteria [19]. The samples were aliquoted and stored 
at − 80 °C until further use. Organ damage was assessed 
by means of the SDI damage index (Systemic Lupus 
International Collaborating Clinics/American College 
of Rheumatology Damage Index) [1] and disease activ-
ity was evaluated by means of SLEDAI (Systemic Lupus 
Erythematosus Disease Activity Index) [20]. Subgroups 
were formed on the basis of (1) the SDI (SDI = 0, n = 33; 
SDI = 1, n = 17; SDI ≥ 2, n = 25), (2) the biopsy-proven 
presence of LN (no LN, n = 48; LN, n = 27), and (3) the 
renal SLEDAI within LN subgroup, where renal SLEDAI 
score of ≥ 4 was taken as an indicator of active LN (inac-
tive LN, n =  14; active LN, n =  13). The renal SLEDAI 
consists of the four renal parameters: hematuria, pyuria, 
proteinuria, and urinary casts [20]. The mean of LN dura-
tion in active LN patients was 7 years (range 0–19 years) 
and in inactive LN patients 8  years (range 1–18  years). 
The demographic and clinical features are described in 
Table 1. The age-matched control group of healthy sub-
jects comprised 23 medical staff members (mean age 40, 
range 26–73, female/male 15/8), who gave statements 
about their health status and excluded any medication 
used for SLE treatment (corticosteroids, antimalarials, 
immunosuppressant drugs). The patients and control 
subjects provided written informed consent about the 
usage of peripheral blood for the purpose of this study, 
which was approved by the ethics committee of the Uni-
versity Hospital and Palacky University Olomouc.
Proximity extension immunoassay (PEA)
The serum levels of 92 inflammation-related proteins 
were simultaneously measured by a PEA using the Pro-
seek Multiplex Inflammation kit I (Olink Bioscience, 
Sweden) according to the manufacturer’s recommenda-
tion. Briefly, each analyte is recognized by a pair of oli-
gonucleotide-labelled antibodies and when binding to 
their correct targets, they give rise to reporter amplicons 
which are amplified and quantified by microfluidic-based 
real-time PCR (BioMark™ HD System, Fluidigm Corpo-
ration). The data obtained is normalized and used for the 
relative quantification of the concentration of each ana-
lyte [26, 27]. The PEA kits offer the same level of perfor-
mance as ELISA and comparable sensitivity to standard 
ELISA kits with much less sample and a higher dynamic 
range. For a panel description see Additional file 1: Table 
S1; for the sensitivity and specificity parameters of the 
PEA analysis see [26, 27].
Statistics
All statistical analyses were performed on linearized 
data (linear ddCq) for each analyte. Statistical tests 
(Mann–Whitney–Wilcoxon test, Benjamini–Hochberg 
correction, Spearman correlations, Receiver Operating 
Characteristic (ROC) curve analysis, and Bayesian prob-
ability model) were performed using the R statistical soft-
ware with the Caret package (http://www.r-project.org/; 
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http://topepo.github.io/caret/index.html). The P value for 
each protein was adjusted for multiple comparisons using 
the False Discovery Rate by the Benjamini–Hochberg 
procedure. Pcorr value < 0.05 was considered significant.
Results
Protein pattern of SLE
 In order to assess the serum protein fingerprint asso-
ciated with SLE, we compared the serum protein lev-
els obtained by PEA immunoassay in the SLE patients 
and healthy controls. Of 92 biomarkers that were ana-
lyzed, the levels of 14 analytes (IL1A, IL2, sIL2RB, IL4, 
IL5, IL13, IL20, sIL20RA, IL33, TSLP, ARTN, TNF, LIF, 
NRTN) were below the limit of detection in our sam-
ple set and therefore they were excluded from further 
analysis. Comparing SLE and the controls, 29 proteins 
were upregulated and sDNER downregulated in SLE 
(Pcorr < 0.05; Table 2a, Additional file 1: Table S2). The dis-
tribution of the serum levels of top-upregulated proteins 
(sirtuin 2, IL18, caspase 8, sCD40/sTNFRSF5, sSLAMF1, 
sTNFRSF9, axin 1, sulfotransferase 1A1, STAMBP, 
CCL19/MIP-3ß, IL10, and CCL4/MIP-1β; Pcorr < 0.003) is 
shown in Fig. 1. For the serum protein pattern associated 
with SLE and the changes in protein levels between SLE 
and the controls for top-deregulated analytes see Figs. 2a 
and 3a.   
Because of the suggested central role of the IFN path-
way in SLE pathogenesis by promoting feedback loops 
progressively disrupting peripheral immune tolerance 
and driving disease activity [28, 29], we investigated the 
IFN protein “signature” of nine IFN-regulated cytokines. 
Because of the reported association of an increased IFN 
gene expression “signature” with disease activity [28, 29], 
we performed correlation analysis among the protein lev-
els of IFN-regulated chemokines and disease activity as 
assessed by SLEDAI. The analysis revealed elevation of 
six IFN-regulated cytokines (IL6, CCL2/MCP1, CCL3/
MIP-1α, sCD40, CXCL11, and CCL19; Pcorr  ≤  0.01) in 
SLE and three (CCL8/MCP2, CXCL9, and CXCL10) did 
not reach significance (Pcorr > 0.05). Interestingly, only a 
mild positive correlation (r = 0.25, P = 0.03; Additional 
file 1: Table S3) was observed between the levels of IFN-
regulated chemokines and disease activity as assessed by 
SLEDAI. Disease activity assessed by SLEDAI correlated 
Table 1 Demographic and clinical characteristics of enrolled SLE patients and subgroups based on the presence of organ 
damage and LN
*SLICC/ACR Damage Index (SDI) was used as a measure of irreversible organ damage in SLE [1]
@ Defined by the ACR nomenclature [21]
# Defined by the ACR classification criteria [19]
§ Defined as documented pericarditis or myocarditis with compromised left ventrical function or valvular disease
† Skin involvement defined by Gillian´s criteria [22] and arthritis by ACR definition [19]
$ Defined by preliminary classification criteria for antiphospholipid syndrome [23]
& Renal SLEDAI score of ≥ 4 was taken as an indicator of active LN [24, 25]
Demographic and clinical features SLE (n = 75) Organ damage (n = 42) No organ damage (n = 33) LN (n = 27) No LN (n = 48)
Female/Male 66/9 34/8 32/1 22/5 44/4
Age (years) mean (min–max) 40 (19–74) 44 (20–67) 35 (19–74) 35 (19–57) 46 (25–64)
Age at the onset of the disease (years) mean 
(min–max)
27 (11–58) 31 (11–58) 26 (12–56) 24 (12–55) 33 (11–58)
Duration of the disease (years) mean  
(min–max)
11 (1–38) 13 (1–38) 10 (1–31) 11 (1–20) 13 (1–38)
Organ damage (SDI ≥ 2/SDI = 1/SDI = 0)* 25/17/33 25/17/0 0/0/33 10/5/12 15/12/21
Organ damage: SDI mean (min–max) 1.2 (0–8) 2.2 (1–8) 0 (0–0) 1.1 (0–5) 1.3 (0–8)
Lupus nephritis, biopsy proven (Y/N) 27/48 15/27 12/21 27/0 0/48
Neurological involvement (Y/N)@ 22/53 15/27 7/26 9/18 13/35
Hematological involvement (Y/N)# 19/56 15/27 4/29 5/22 14/34
Cardiovascular involvement (Y/N)§ 12/63 11/31 1/32 4/23 8/40
Skin and musculoskeletal involvement 
(Y/N)†
56/19 28/14 28/5 6/21 35/13
Antiphospholipid syndrome (Y/N)$ 23/52 15/27 8/25 6/21 17/31
Renal disorder (Y/N)# 35/40 19/23 12/21 27/0 9/39
Disease activity: SLEDAI mean (min–max) 7 (0–43) 8.8 (0–43) 4.7 (0–26) 10.3 (0–43) 5.2 (0–20)
Active/inactive renal  disease& 17/58 12/30 5/28 13/14 4/44
Mean of cumulative dose of glucocorticoids 
(g) (min–max)
22.8 (0–79.2) 30.6 (2.6–79.2) 12.8 (0–54.0) 27.2 (2.4–68.4) 20.3 (0–79.2)
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Table 2 Serum levels of  proteins differentiating between  a healthy controls vs SLE, b SLE patients with  organ damage 
(SDI ≥ 1) vs those without organ damage (SDI = 0), c patients with biopsy-proven active lupus nephritis (active LN) vs 
patients without  lupus nephritis (no LN), d patients with  biopsy-proven active lupus nephritis (active LN) vs patients 
with inactive biopsy-proven lupus nephritis (inactive LN)
a Healthy controls vs SLE
Analyte Mean linear ddCq (95% CI) FC P Pcorr
Healthy controls SLE
SIRT2 8.31 (6.49–10.1) 19.8 (15.5–24.0) 2.33 6.5 × 10−6 5.1 × 10−4
IL18 183 (155–212) 287 (257–316) 1.67 1.6 × 10−5 6.2 × 10−4
CASP8 2.04 (1.88–2.20) 2.99 (2.68–3.30) 1.37 2.5 × 10−5 6.3 × 10−4
sCD40 527 (466–588) 735 (639–831) 1.29 3.2 × 10−5 6.3 × 10−4
sSLAMF1 5.10 (4.0–6.19) 6.52 (6.0–7.05) 1.39 9.0 × 10−5 1.1 × 10−3
sTNFRSF9 87.8 (75.2–100) 141 (123–159) 1.54 1.1 × 10−4 1.1 × 10−3
ST1A1 3.36 (2.04–4.69) 8.04 (6.66–9.43) 2.41 1.3 × 10−4 1.1 × 10−3
STAMBP 12.1 (10.1–14.1) 18.9 (16.1–21.8) 1.42 1.5 × 10−4 1.1 × 10−3
CCL19 804 (394–1215) 1646 (1326–1966) 2.04 1.5 × 10−4 1.1 × 10−3
IL10 8.33 (6.94–9.72) 17.8 (10.4–25.1) 1.38 3.7 × 10−4 2.6 × 10−3
CCL4 77.7 (63.8–91.6) 123 (109–138) 1.46 4.2 × 10−4 2.7 × 10−3
IL12B 17.3 (13.3–21.4) 29.3 (25.1–33.5) 1.96 5.7 × 10−4 3.4 × 10−3
IL6 4.18 (3.28–5.09) 26.9 (−0.62–54.4) 1.67 7.0 × 10−4 3.9 × 10−3
CCL3 9.58 (4.47–14.7) 35.8 (−11.2–82.9) 1.51 7.6 × 10−4 4.0 × 10−3
CXCL11 187 (142–232) 343 (279–408) 1.58 1.1 × 10−3 5.4 × 10−3
sPDL1 3.43 (3.19–3.67) 4.24 (3.91–4.57) 1.28 1.2 × 10−3 5.4 × 10−3
sIL18R1 106 (90.1–122) 139 (126–152) 1.28 1.4 × 10−3 6.0 × 10−3
sCX3CL1 86.9 (74.8–99.0) 131 (108–153) 1.39 2.2 × 10−3 9.0 × 10−3
sDNER 170 (161–179) 150 (143–157) 0.91 2.6 × 10−3 1.0 × 10−2
sIL15RA 1.90 (1.68–2.13) 2.43 (2.19–2.66) 1.23 2.9 × 10−3 1.1 × 10−2
CSF1 241 (223–259) 281 (270–293) 1.11 3.3 × 10−3 1.2 × 10−2
sLIFR 8.35 (7.84–8.85) 10.3 (8.94–11.6) 1.04 3.4 × 10−3 1.2 × 10−2
IL8 236 (199–273) 383 (281–485) 1.27 3.9 × 10−3 1.2 × 10−2
CCL2 2133 (1801–2465) 3054 (2660–3449) 1.26 3.9 × 10−3 1.2 × 10−2
FGF23 2.77 (2.63–2.91) 4.32 (2.95–5.70) 1.01 5.8 × 10−3 1.8 × 10−2
LAP.TGFB1 131 (117–146) 158 (148–167) 1.28 6.6 × 10−3 1.9 × 10−2
sTRAIL 517 (470–565) 602 (568–636) 1.20 1.1 × 10−2 3.1 × 10−2
MMP10 98.5 (81.5–116) 156 (128–184) 1.34 1.4 × 10−2 3.7 × 10−2
CCL7 5.70 (4.57–6.83) 12.5 (7.31–17.7) 1.38 1.6 × 10−2 4.1 × 10−2
b SDI = 0 vs SDI ≥ 1
Analyte Mean linear ddCq (95% CI) FC P Pcorr
SDI = 0 SDI ≥ 1
IL8 286 (215–358) 459 (286–632) 1.32 2.7 × 10−5 2.1 × 10−3
CCL2 2485 (2011–2960) 3502 (2924–4080) 1.50 4.3 × 10−4 1.6 × 10−2
IL6 8.28 (3.95–12.6) 41.5 (−7.95–91.0) 1.98 6.5 × 10−4 1.6 × 10−2
CCL11 273 (247–299) 344 (315–373) 1.30 8.0 × 10−4 1.6 × 10−2
FGF21 56.1 (28.8–83.4) 257 (57.1–456) 2.43 1.0 × 10−3 1.6 × 10−2
MMP10 112 (93.4–131) 190 (144–237) 1.24 2.4 × 10−3 3.1 × 10−2
IL18 255 (208–302) 311 (274–349) 1.19 3.7 × 10−3 4.1 × 10−2
CCL3 9.70 (8.24–11.2) 56.4 (−28.7–142) 1.32 4.8 × 10−3 4.4 × 10−2
FGF5 2.25 (2.13–2.37) 2.72 (2.31–3.12) 1.08 5.1 × 10−3 4.4 × 10−2
FGF23 3.75 (2.51–5.00) 4.77 (2.47–7.06) 1.15 5.7 × 10−3 4.4 × 10−2
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better with the following analytes: IL8, GDNF, CX3CL1/
fractalkine (r  ≥  0.403, P  ≤  0.0003), and CCL7/MCP3, 
IL15RA, VEGFA, and MMP10 (r  ≥  0.355, P  ≤  0.002; 
Additional file 1: Table S3).
Protein pattern of organ damage
To obtain the protein pattern associated with organ dam-
age, we compared the serum patterns from SLE patients 
with/without organ damage and subgroups according to 
the SDI (SDI ≥ 2/SDI = 1/SDI = 0).
 The distribution of damaged organs in our patient 
group and reported cohorts is shown in Additional file 1: 
Figure S1, Table S4. In the patients with organ dam-
age (SDI  ≥  1), elevated serum levels of IL8, CCL2, IL6, 
CCL11/eotaxin, FGF21, MMP10, IL18, CCL3, FGF5, and 
FGF23 (Pcorr < 0.05) were detected (Table 2b, Fig. 4). The 
serum protein pattern associated with organ damage and 
the changes in protein levels between SLE patients with/
without organ damage are shown in Figs.  2b and 3b. 
Although the serum level of CCL11 did not differ between 
the controls and SLE patients as a whole, the patients with 
organ damage had higher levels of CCL11 in comparison 
to those with no organ damage, as well as to the control 
group (Additional file 1: Figure S2a). We did not observe 
differences in serum protein pattern between patients 
with SDI = 1 and SDI ≥ 2 (data not shown).
Among organ damage associated analytes, the 
cumulative dose of glucocorticoids correlated posi-
tively with levels of IL8, CCL11 (r ≥ 0.326, P ≤ 0.004), 
CCL2 and MMP10 (r  ≥  0.249, P  <  0.05; Additional 
file 1: Table S3). Additionaly, cumulative dose of glu-
cocorticoids correlated with BDNF, CCL25, CXCL1, 
GDNF, IL17C, sADA, sCDCP1, sIL18R1, sSCF, and 
sTGFA (P < 0.05; Additional file 1: Table S3). Moreo-
ver, IL8 (r =  0.416, P =  0.0002), MMP10 (r =  0.355, 
P  =  0.002), CCL2, and CCL11 (r  ≥  0.261, P  ≤  0.02; 
Additional file  1: Table S3) correlated positively with 
disease activity. In line with other reports, a higher 
cumulative dosage of glucocorticoids was registered 
in the patients with SDI  ≥  1 (mean of 30.6  g, min–
max 2.6–79.2  g) compared with those without dam-
age (12.8, 0–54.0). Regarding association of disease 
duration and serum levels of studied proteins, we 
observed only mild association for CCL11 (r = 0.230, 
P = 0.047). The disease duration in SLE patients cor-
related with SDI (r = 0.298, P = 0.009).
Table 2 continued
c No LN vs active LN
Analyte Mean linear ddCq (95% CI) FC P Pcorr
No LN Active LN
CSF1 266 (254–278) 340 (310–370) 1.27 4.0 × 10−5 2.7 × 10−3
sIL15RA 2.17 (2.03–2.32) 3.65 (2.57–4.73) 1.43 9.0 × 10−5 2.7 × 10−3
sCD40 645 (595–695) 1116 (587–1645) 1.48 1.0 × 10−4 2.7 × 10−3
sCX3CL1 103 (93.2–112) 247 (134–359) 1.62 2.8 × 10−4 5.4 × 10−3
CASP8 2.80 (2.39–3.21) 3.84 (3.06–4.73) 1.49 1.1 × 10−3 1.7 × 10−2
sIL18R1 129 (119–139) 186 (121–251) 1.26 1.9 × 10−3 2.3 × 10−2
bNGF 2.66 (2.47–2.84) 3.66 (2.96–4.36) 1.41 2.2 × 10−3 2.3 × 10−2
GDNF 4.66 (4.37–4.96) 6.16 (4.98–7.33) 1.32 2.3 × 10−3 2.3 × 10−2
d Inactive LN vs active LN
Analyte Mean linear ddCq (95% CI) FC P Pcorr
Inactive LN Active LN
sIL15RA 2.15 (1.82–2.48) 3.65 (2.57–4.73) 1.56 8.9 × 10−4 6.9 × 10−2
CSF1 280 (253–306) 340 (310–370) 1.28 4.7 × 10−3 0.15
bNGF 2.64 (2.43–2.85) 3.66 (2.96–4.36) 1.29 4.7 × 10−3 0.15
sIL18R1 73.4 (66.2–80.5) 186 (121–251) 1.31 6.6 × 10−3 0.15
sCD40 688 (636–740) 1116 (587–1645) 1.32 1.2 × 10−2 0.18
sCX3CL1 118 (93.6–143) 247 (134–359) 1.42 2.3 × 10−2 0.25
CASP8 2.84 (2.42–3.26) 3.84 (3.06–4.73) 1.33 2.3 × 10−2 0.25
Pcorr value corrected for multiple comparisons (Benjamini–Hochberg correction)
FC (fold-change) between group medians of linear ddCq
Page 6 of 15Petrackova et al. Clin Proteom  (2017) 14:32 
Fig. 1 Distribution of serum levels for top-deregulated proteins between healthy controls and SLE. Group means are indicated by horizontal bars, 
error bars indicate 95% CI; Pcorr values after multiple corrections are stated
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Fig. 2 Protein serum fingerprints associated with a SLE, b organ damage, and c active lupus nephritis (LN). Fingerprints are presented as FC (fold-
change of group medians) of serum levels of all deregulated serum proteins between particular groups (Pcorr < 0.05)
Fig. 3 Changes in protein levels for top-deregulated analytes between a SLE and controls, b patients with/without organ damage, and c patients 
with active lupus nephritis and without lupus nephritis (no LN). Changes are presented as percentage of changes between group medians of 
particular groups
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Fig. 4 Distribution of serum levels of proteins distinguishing SLE patients with/without organ damage. Group means are indicated by horizontal 
bars, error bars indicate 95% CI; Pcorr values for differences after multiple corrections are stated
Page 9 of 15Petrackova et al. Clin Proteom  (2017) 14:32 
Protein pattern of active lupus nephritis and other clinical 
subsets of SLE
To investigate the serum patterns associated with active 
LN, we compared subgroups of SLE patients with/with-
out biopsy-proven LN and subgroups of patients with 
LN classified by the renal SLEDAI as active (renal SLE-
DAI ≥ 4) or inactive renal disease at the day of sampling. 
Moreover, we assessed serum patterns associated with 
other clinical subsets of SLE as neurological, hemato-
logical, cardiovascular, skin and musculoskeletal involve-
ments, antiphospholipid syndrome, and renal disorder.
The analysis in biopsy-proven LN patients with active 
renal disease revealed elevated protein levels of CSF1, 
sIL15RA, sCD40, sCX3CL1, caspase 8, sIL18R1, bNGF, 
and GDNF compared to those without LN (Table  2c, 
Fig. 5). Although the serum levels of GDNF did not differ 
Fig. 5 Distribution of serum levels of proteins distinguishing SLE patients without lupus nephritis (LN), with inactive lupus nephritis (inactive LN) 
and active lupus nephritis (active LN). Group means are indicated by horizontal bars, error bars indicate 95% CI
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between the control group and SLE as a whole, its level 
was enhanced in the patients with LN in comparison 
to those without LN and the control group (Additional 
file 1: Figure S2b). The serum protein pattern associated 
with active LN and the changes in protein levels between 
the SLE patients without LN and active LN are shown in 
Figs. 2c and 3c.
When LN patients with active renal disease was com-
pared to inactive LN subgroup, elevation of sIL15RA, 
CSF1, bNGF, sIL18R1, sCD40, sCX3CL1, and caspase 8 
(P < 0.05, Table 2d, Fig. 5), but not GDNF, in active LN 
patients was observed.
In the other studied clinical subsets no differences in 
the serum pattern were detected. The subanalysis con-
firmed that no candidate biomarker for SLE, organ dam-
age and/or LN are influenced by the gender (data not 
shown).
Identification of patients with a high probability of organ 
damage and active lupus nephritis
To investigate the utility of the serum levels of pheno-
type-associated proteins for the identification of patients 
with a high probability of severe phenotypes, we con-
structed probability plots for phenotype-associated 
proteins based on a Bayesian statistical approach. Addi-
tionally, we constructed ROC curves for the proteins 
associated with organ damage and active LN.
In organ damage, the best predictive model was 
observed for the serum levels of CCL11 and MMP10, fol-
lowed by CCL2, whereas IL6 and IL8 were not informa-
tive (Fig. 6). Higher serum levels of CCL11 and MMP10 
correspond to a higher probability of organ damage. For 
the analytes associated with organ damage, the ROC 
curve analysis showed that the area under the curve 
(AUC) of IL8, CCL2, IL6, CCL11, FGF21, MMP10, IL18, 
CCL3, FGF5, and FGF23 was 0.784, 0.738, 0.731, 0.727, 
0.723, 0.706, 0.697, 0.691, 0.689, and 0.676, respectively 
(Additional file  1: Figure S3a; for sensitivity, specificity, 
and other parameters see Additional file 1: Table S5a).
In active LN, the best predictive value was observed 
for CSF1, sIL15RA, sCD40, sCX3CL1, caspase 8, and 
sIL18R1 (Fig.  7). Higher serum levels of all these ana-
lytes correspond to a higher probability of the presence 
of active LN. For the analytes associated with active LN, 
the ROC curve analysis showed that the AUC of CSF1, 
sIL15RA, sCD40, sCX3CL1, caspase 8, sIL18R1, bNGF, 
and GDNF were 0.873, 0.857, 0.854, 0.832, 0.798, 0.783, 
0.780, and 0.778, respectively (Additional file  1: Figure 
S3b, Table S5b). Moreover, we observed great sensitivity 
and specificity for proteins sIL15RA (AUC: 0.879, sensi-
tivity: 100%, specificity: 64.3%), CSF1 (0.813, 84.6, 78.6), 
sIL18R1 (0.810, 84.6, 78.6), and bNGF (0.805, 69.2, 100) 
showing good discrimination between active and inactive 
renal disease in LN patient subgroup (Additional file  1: 
Fig. 6 Probability plots of serum analytes associated with organ damage in SLE patients. The grey curve represents a simulated model based on 
the individual patient serum levels and the black line represents overall trend calculated by the Bayesian statistical approach. The increasing overall 
trend the higher probability of organ damage. Higher serum levels of CCL11 and MMP10 correspond to higher probability of organ damage, lower 
serum levels of these analytes to lower probability of organ damage. IL8 and IL6 serum levels were not informative for organ damage prediction
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Figure S3c, Table S5c). Inactive LN patients do not dif-
fer from patients without LN, except for GDNF (Fig. 5), 
suggesting that serum GDNF level remains elevated even 
when LN is inactive.
All nominated biomarkers associated with organ 
damage and active LN showed better discrimination 
ability in our cohort than the classical markers (Addi-
tional file 1: Table S6). The only exception was protein-
uria (AUC 0.869), one of the criteria for renal SLEDAI 
classification.
Discussion
Using innovative highly sensitive multiplex PEA analysis 
on 92 inflammation-related proteins, we identified the 
serum protein pattern associated with SLE, with many 
proteins not yet reported in this disease. Moreover, we 
identified the serum patterns associated with irrevers-
ible organ damage and active LN and identified proteins 
showing utility for the identification of patients at risk of 
these severe disease manifestations.
This serum protein study in SLE patients revealed 
the deregulation of 30 proteins in SLE. The major-
ity of the upregulated proteins were known inflamma-
tory mediators: IL6, IL10 [30], IL18 [31], CX3CL1 [32], 
CCL2 [33], CCL3, CCL7, CCL19 [34], and FGF23 [35] 
already reported in SLE previously. Interestingly, the 
most upregulated proteins—sirtuin 2 and caspase 8—
were not associated with SLE or even with any autoim-
mune disease. However, recent reports in animal models 
and cell lines support their involvement in inflammation 
and autoimmunity. Regarding sirtuin 2, macrophages 
expressing this protein produced more iNOS/NO upon 
LPS stimulation than those with depleted sirtuin 2 [36]. 
This result was also confirmed in vivo, where WT mice 
responded to LPS by increased NO levels and a higher 
amount of M1-macrophages compared to sirtuin 2 KO 
mice [36]. Elevated sirtuin 2 also contributed to pro-
longed hypoinflammation in a septic murine model [37]. 
Regarding caspase 8, a protein widely recognized for its 
role in apoptosis, recent reports identify this enzyme as 
a crucial regulator of inflammation through NFκB acti-
vation and cleavage of pro-IL1β and/or pro-IL18, simi-
larly to caspase 1 [38, 39]. These observations lead us to 
suggest that caspase 8 may also promote autoimmunity 
by stimulating IL17 production by T cells, as shown for 
caspase 1 [40]. Moreover, the therapeutic potential of 
caspase 8 is supported by the observation of attenuated 
retinal ischemic damage resulting from the inhibition of 
caspase 8, resulting in the blockade of IL1β production 
[41]. However, there is evidence about the pleiotropic 
effects of sirtuin 2 and caspase 8, and thus future studies 
on their role in SLE are needed.
Fig. 7 Probability plots of serum analytes associated with active lupus nephritis (LN) in SLE patients. The grey curve represents a simulated model 
based on the individual patient serum levels and the black line represents overall trend calculated by the Bayesian statistical approach. The increas-
ing overall trend the higher probability of active LN. Higher serum levels correspond to higher probability of active LN, lower serum levels of these 
analytes to lower probability of active LN. The best predictive value was observed for CSF1, sIL15RA, sCD40, sCX3CL1, caspase 8 (CASP8), and 
sIL18R1
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Further highly upregulated proteins, IL18 and sul-
fotransferase 1A1, were already reported in autoim-
munity. An elevated IL18 serum level was reported in 
SLE [42], especially in LN patients [43, 44]. Regarding 
sulfotransferase 1A1, higher activity was found in auto-
immune thyroid disease glands compared to normal 
thyroids [45], but no information yet exists in SLE. Inter-
estingly, we did not detect any elevation of the serum 
level of the previously reported SLE-associated factor 
TWEAK and IFNγ [46, 47]. Despite the reported asso-
ciation of the IFN gene expression “signature” with dis-
ease activity in SLE [28, 29], we did not confirm either 
elevated levels of the IFN-regulated chemokines CCL8, 
CXCL9, CXCL10 or strong correlation of the IFN protein 
“signature” with disease activity at the protein level in the 
sera of our patients. Our observation is in line with oth-
ers [28], thus supporting the opinion that cytokine levels 
in serum are a less sensitive readout for activation of the 
IFN pathway than the gene expression “signature”.
Despite tremendous efforts, the greatest challenges still 
remain in the management of SLE patients with severe 
organ damage and active LN. Thus, there is a need to 
identify novel biomarkers that will better facilitate the 
assessment of organ involvement and disease activity. In 
our study, SLE patients with organ damage had elevated 
serum levels of IL8, CCL2, IL6, CCL11, FGF21, MMP10, 
IL18, CCL3, FGF5, and FGF23 compared to those with-
out organ damage. Of these, enhanced levels of CCL11, 
MMP10, and CCL2 were informative for the identifica-
tion of patients with organ damage. Importantly, CCL11, 
MMP10, and CCL2 also correlated with disease activ-
ity. The elevation of the chemokine CCL11 was already 
associated with damage to various organs, as shown in 
idiopathic retroperitoneal fibrosis [48] and liver cirrhosis 
patients [49]. Moreover, in murine models of lung fibro-
sis [50], as well as of eosinophilic myocarditis [51], the 
blockade of the CCL11-CCR3 pathway prevented organ 
damage. Similarly, MMP10 was linked to renal damage 
[52] and tissue destruction in arthritis [53]. Elevation of 
MMP10 was already reported in SLE patients [54] and 
in a murine LN model with glomerulonephritis [55]. 
Another protein associated with organ damage, CCL2, 
was already reported in kidney damage in lupus murine 
models [56] and in SLE patients with irreversible renal 
damage [57]. Although IL6 and IL8, cytokines involved 
in the pathogenesis of SLE, were also enhanced in our 
patients with organ damage, our analysis did not sup-
port their predictive value for this severe phenotype. The 
usefulness of CCL11, MMP10, and CCL2 as biomarkers 
or possible treatment targets needs to be elucidated in 
future studies.
Lupus nephritis is considered another challenging SLE 
phenotype from the point of view of its prediction and 
preemptive diagnostics. Renal biopsy is still the gold 
standard to assess the renal involvement of SLE and its 
severity and pathological category [8]. The search for 
non-invasive biomarkers in serum and urine reflecting 
the renal disease activity is therefore a major focus of 
interest. Our serum protein analysis in LN patients with 
active renal disease revealed upregulated levels of CSF1, 
sIL15RA, sCD40, sCX3CL1, caspase 8, sIL18R1, bNGF, 
and GDNF compared to those without LN. All these 
markers showed excellent discrimination for active LN, 
significantly better than the classical markers as shown 
by us and others [9, 10]. Moreover, we observed good 
discrimination between active and inactive renal dis-
ease in LN patient subgroup for all markers, except for 
GDNF. Apart from caspase 8 and sIL15RA, emerging 
evidence of the active involvement of these proteins 
in LN already exists. Regarding CSF1, elevated serum 
levels in patients with SLE were shown to reflect kid-
ney histopathology and to predict renal disease activ-
ity [58]. Moreover, CSF1 deficiency protected against 
LN in murine models [59]. Enhanced protein and gene 
expression of IL15RA was detected in leucocytes from 
SLE patients [60, 61], probably as a results of hydroxy-
methylation in promoter region of this gene in SLE 
[61]. There is also evidence about the crucial role of 
the CD40-CD40L system in the development, progres-
sion and outcome of SLE [62]. Enhanced CD40L pro-
tein level was detected in sera from SLE patients [62, 
63] as well as class III and IV LN and other inflamma-
tory renal diseases [64]. Moreover, CD40 gene silenc-
ing reduced the progression of experimental LN [65]. 
Regarding sCX3CL1, elevated expression was reported 
in proliferative LN [66] and the administration of a 
CX3CL1 antagonist to mice delayed the initiation and 
ameliorated the progression of LN [67]. Also enhanced 
expression of IL18R1 has already been reported in SLE 
patients [68] as well as in peripheral plasmacytoid DCs 
in active LN patients [69]. Similarly, increased levels of 
NGF, a complex of 3 subunits—aNGF, bNGF, and gNGF, 
has been reported in the sera of SLE patients [70] and 
various renal disorders [71]. Regarding GDNF, a high 
expression of this protein was detected in renal biop-
sies from patients with proteinuric nephropathy [72] 
and increased plasma levels of GDNF were reported in 
patients with chronic renal diseases [73]. This mesan-
gial autocrine growth factor was shown to play a pivotal 
role in mesangial cell proliferation, which is essential 
for the progression of various glomerular diseases [74]. 
Our study did not confirm IL18 as a useful biomarker to 
assess the activity of renal disease, as reported by oth-
ers [42, 43]. On the other hand, our results nominated 
spectrum of novel biomarkers of renal involvement for 
further confirmation studies.
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Althougth relatively high sensitivity and specificity was 
obtained for each individual marker in our LN and organ 
damage subgroups, we believe that using rather a panel 
of multiple biomarkers and/or combination with other 
clinical and laboratory parameters would be an appropri-
ate approach in the identification of patients with these 
severe manifestations.
Conclusions
This exploratory study revealed many novel proteins 
associated with SLE for future immunopathogenesis 
studies, as well as nominating candidate biomarkers for 
irreversible organ damage and active lupus nephritis. 
Future studies on larger cohorts with well-defined phe-
notypes as well as the longitudinal follow-up during dis-
ease development are needed to prove the suitability of 
these proteins or their combinations as biomarkers for 
organ damage and lupus nephritis, with special emphasis 
on disease activity.
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